Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Galera Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
18.7
42.3
54.8
52.4
31
24.1
3.15
0.35
General and administrative
5.59
8.36
15.7
21
20.2
22.8
11
5.69
Operating income
-24.3
-50.7
-70.6
-73.4
-51.2
-49.3
-20.2
-2.54
Interest expense
0.22
3.03
4.88
7.19
11.6
11.4
0
0
Interest income
0.61
1.82
1.17
0.03
0.51
1.6
0.55
0.25
Pre-tax income
-23.9
-51.9
-74.2
-80.5
-62.3
-59.1
-19.2
149
Income tax
-0.22
-0.01
-0.02
0
0.07
0
-0.2
0
Net income
-23.7
-51.9
-74.2
-80.5
-62.2
-59.1
-19
149
EBITDA
-24.1
-50.4
-70.2
-72.6
-51.1
-49
-20.1
-2.54
EPS, basic
-98.42
-16.31
-2.98
-3.12
-1.33
-0.34
0.64
EPS, diluted
-98.42
-16.31
-2.98
-3.12
-1.33
-0.34
0.64
Shares, basic (weighted)
0.3
3.63
24.9
25.8
44.5
54.6
98.5
Shares, diluted (weighted)
0.3
3.63
24.9
25.8
44.5
54.6
98.5
Balance sheet
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
14.8
18.4
15.9
19.9
4.27
18.3
8.29
6.38
Short-term investments
66.7
93.9
56.9
51.4
27.3
0
Other current assets
1.47
5.28
5.15
6.18
3.65
3.37
1.08
0.72
Total current assets
83.9
118
77.9
77.4
38.5
21.6
10
7.1
Property, plant and equipment
0.57
0.93
1.02
0.53
0.44
0.07
0
Lease right-of-use assets
0.82
0.53
0.3
0.04
1.21
0
Goodwill
0.88
0.88
0.88
0.88
0.88
0.88
0
Intangible assets
2.26
2.26
2.26
Other non-current assets
0.5
0.92
1.48
1.96
1.88
0.09
0.1
0.1
Total assets
88.1
123
84.1
83.3
44
26.1
10.1
7.2
Accounts payable
3.87
3.95
5.15
5.04
3.58
1.38
1.28
0.27
Accrued liabilities
2.58
5.45
8.58
7.63
9.75
3.45
0.39
0.38
Short-term debt
0.3
0.24
0.26
0.04
0.13
0
Total current liabilities
6.44
9.69
14
12.9
13.4
4.96
1.67
0.65
Lease liabilities
0.53
0.3
0.04
0
1.12
0
Total liabilities
27
53.8
78
141
153
157
154
0.65
Total debt
0.3
0.24
0.26
0.04
0.13
0
Paid-in capital
231
242
258
269
306
308
311
Retained earnings
-105
-161
-236
-316
-378
-437
-456
-307
Other comprehensive income
0
0.04
0.01
-0.01
-0.02
0
Shareholders' equity
-105
69.6
6.12
-58
-109
-131
-148
3.97
Total equity
-105
69.6
6.12
-58
-109
-131
-148
3.97
Total liabilities and equity
88.1
123
84.1
83.3
44
26.1
10.1
7.2
Shares outstanding
0.3
24.8
25
26.5
28.5
54.4
75.5
75.5
Cash flow statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-23.7
-51.9
-74.2
-80.5
-62.2
-59.1
-19
149
Depreciation and amortization
0.13
0.27
0.37
0.78
0.11
0.26
0.02
0
Stock-based compensation
0.87
2.39
5.54
7.23
7.16
5.56
2.55
0.41
Deferred income tax
-0.22
-0.01
-0.02
0
-0.07
0
-0.2
0
Change in payables
1.59
0.08
1.2
-0.1
-1.46
-2.21
-1.42
-1.01
Cash from operations
-22.2
-46.7
-59.5
-68
-43.4
-44.8
-12.1
-6.05
Capital expenditures
-0.35
-0.63
-0.46
-0.28
-0.03
-0.06
0
Purchases of investments
-71.2
-123
-67.7
-72
-59.9
0
-0.05
0
Cash from investing
-59
-27.8
36.5
5.24
24
27.3
-0.05
3.5
Stock issued
0.01
0.51
1.27
0.08
1.7
0
Cash from financing
89.8
78
20.5
66.7
3.89
31.5
2.22
0.64
Net change in cash
8.64
3.55
-2.48
3.99
-15.5
13.9
-9.97
-1.91
Free cash flow
-22.5
-47.3
-60
-68.2
-43.5
-44.9
-12.1
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to March 31, 2026; growth uses fiscal years. Valuation uses the share price of $18.99 on August 3, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
20,472.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
2,418.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value CAGR, 5y
-8.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-28.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-45.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-38.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
80.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
31.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.05
Cash from operations / diluted weighted shares.
Book value per share
$0.01
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
20.4x
Market cap / net income. Only when net income is positive.
P/B
4,185x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4,185x
Market cap / tangible book value, when positive.
Earnings yield
4.9%
Net income / market cap (the inverse of P/E).
Was Galera Therapeutics, Inc. profitable in fiscal 2025?
Yes. Net income was $149.0M, a net margin of -.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.